Fujifilm Biotechnologies has announced the opening of its manufacturing site in Holly Springs, North Carolina, US. The newest addition to Fujifilm Biotechnologies’ global network represents one of the largest commercial-scale cell culture biomanufacturing sites in North America.
The first phase of the planned $3.2 billion manufacturing site opens with a capacity of 8 x 20,000 liters (L) mammalian cell culture bioreactors to encompass drug product and drug substance manufacturing, while adding finished goods capabilities in 2026.
The second phase expansion (announced in 2024) will double capacity with an additional 8 x 20,000 L bioreactors for a total of 16 bioreactors.
"Fujifilm's total global investment of over $8 billion to expand our contract development and manufacturing organization (CDMO) business underscores our unwavering commitment to advancing life sciences for our partners, people, and patients. Our new commercial-scale manufacturing hub in the US highlights Fujifilm’s dedication to supporting our partners in delivering biologic medicines targeting complex diseases,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, Fujifilm Corporation, Japan, and chairman, Fujifilm Biotechnologies.
The new, state-of-the-art facility currently employs over 680 employees, and is on track to reach 750 employees by the end of the year, with an overall goal of hiring a total of 1,400 by 2031. Fujifilm Biotechnologies has nearly 5,000 employees worldwide.
